Warner-Lambert retains Zantac 75 North America rights after Glaxo venture dissolves.
This article was originally published in The Tan Sheet
Executive Summary
WARNER-LAMBERT ZANTAC 75 RIGHTS IN NORTH AMERICA RETAINED following dissolution of the firm's joint venture with Glaxo Wellcome for over- the-counter drugs. Under the new arrangement, announced Aug. 3, Warner-Lambert will pay Glaxo Wellcome for the cost of supplying the H2 antagonist ranitidine; there is no royalty component to the agreement. Zantac 75 sales in the U.S. through the half totaled $84 mil. Worldwide sales in 1997 were $161 mil. Zantac 75 is third in the acid blocker market in terms of dollar sales and had a 10.5% market share in 1997 in food, drug and mass merchandise retail channels, according to Information Resources, Inc. (Chicago).